Prestige Consumer Healthcare Inc. announced that Jeffrey Zerillo notified the company of his decision to retire from his position as Senior Vice President, Operations and all other roles, effective August 14, 2026. The filing discloses this executive departure under Item 5.02. Prestige Consumer Healthcare Inc. operates in the consumer health sector, manufacturing and marketing over-the-counter products such as oral care, skin care, and respiratory remedies.

Prestige Consumer Healthcare Inc. reported first-quarter fiscal 2027 results ending June 30, 2026, with revenue of $265.7 million, a 6.5% increase year-over-year, driven by organic growth of 3.2% and contributions from the Breathe Right acquisition. Adjusted diluted EPS was $0.98, up from $0.95 in the prior year period, while adjusted free cash flow reached a record $83.7 million. The company closed its acquisitions of the Breathe Right portfolio and LaCorium Health in June and July 2026, respectively, adding approximately $190 million to expected annual revenue. Consequently, Prestige raised its full-year fiscal 2027 outlook, projecting revenue between $1,290 million and $1,315 million and adjusted diluted EPS between $4.55 and $4.65. The company operates in the consumer healthcare industry, marketing and distributing over-the-counter health products including brands such as Breathe Right, Monistat, and Clear Eyes.

On July 15, 2026, Prestige Brands, Inc., a wholly owned subsidiary of Prestige Consumer Healthcare Inc., issued $400.0 million in 6.250% senior notes due 2034. The notes are senior unsecured obligations of Prestige Brands, Inc. and are guaranteed on an unsecured senior basis by the Company. Prestige Consumer Healthcare Inc. operates in the consumer healthcare industry and manufactures and markets branded products.

Prestige Consumer Healthcare Inc. amended its Term Loan Credit Agreement on July 1, 2026, to permit additional borrowing of up to $95.0 million. The company utilized $95,000,000 of this capacity on the same date to finance the acquisition of several Australian entities, including LaCorium Health Australia Pty Limited and Laderma Holdings Pty Limited. Additionally, the company announced the commencement of a $400,000,000 private offering of senior unsecured notes due 2034 and subsequently confirmed the pricing of these notes following the LaCorium acquisition. Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops and markets branded consumer products.

Prestige Consumer Healthcare Inc. filed this amendment to its June 16, 2026, Form 8-K to provide required historical and pro forma financial statements regarding its June 12, 2026, acquisition of the OTC Wellness Business, including the Breathe Right® brand, from Foundation Consumer Brands, LLC. The filing includes audited combined balance sheets and statements of operations for the acquired business as of December 31, 2025, unaudited condensed financial statements for the period ending March 31, 2026, and unaudited pro forma condensed combined balance sheets and income statements for the company as of March 31, 2026. Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops and markets various branded products.